Literature DB >> 3691623

Plasma free fatty acids and protein binding of disopyramide during haemodialysis.

T Horiuchi1, I Johno, S Kitazawa, M Goto, T Hata.   

Abstract

The binding of disopyramide (DSP) to plasma (or serum) proteins was determined using an ultrafiltration technique in three patients undergoing haemodialysis. An increase in the free fraction (FF) of DSP during dialysis occurred together with elevation of the free fatty acid (FFA) level in plasma. The effect of FFA on protein binding in vitro was examined using DSP- and FFA-spiked solutions containing human alpha 1-acid glycoprotein and serum albumin. The FF of DSP rose in proportion to increasing FFA levels, supporting the in vivo observations. The findings suggest that the free concentration of DSP should be routinely monitored, especially in haemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691623     DOI: 10.1007/bf00637572

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  DETERMINATION OF HEPARIN-INDUCED LIPOPROTEIN LIPASE ACTIVITY IN HUMAN PLASMA.

Authors:  J BOBERG; L A CARLSON
Journal:  Clin Chim Acta       Date:  1964-11       Impact factor: 3.786

2.  Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling.

Authors:  M Wood; D G Shand; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

3.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

4.  Effect of free fatty acids on binding of drugs by bovine serum albumin, by human serum albumin and by rabbit serum.

Authors:  D Rudman; T J Bixler; A E Del Rio
Journal:  J Pharmacol Exp Ther       Date:  1971-02       Impact factor: 4.030

5.  Dialysis death and increased free fatty acids.

Authors:  H Bergrem; T Leivestad
Journal:  Lancet       Date:  1978-11-25       Impact factor: 79.321

6.  Determination of free disopyramide plasma concentrations using ultrafiltration and enzyme multiplied immunoassay.

Authors:  G Raghow; M C Meyer; A B Straughn
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

7.  Protein binding of disopyramide in liver cirrhosis and in nephrotic syndrome.

Authors:  H Echizen; S Saima; N Umeda; T Ishizaki
Journal:  Clin Pharmacol Ther       Date:  1986-09       Impact factor: 6.875

8.  Disopyramide kinetics in renal impairment: determinants of interindividual variability.

Authors:  M Burk; U Peters
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

9.  Blood collection techniques, heparin and quinidine protein binding.

Authors:  K M Kessler; R C Leech; J F Spann
Journal:  Clin Pharmacol Ther       Date:  1979-02       Impact factor: 6.875

10.  Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.

Authors:  D B Haughey; C J Kraft; G R Matzke; W F Keane; C E Halstenson
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

View more
  2 in total

1.  Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.

Authors:  T Horiuchi; I Johno; T Hasegawa; S Kitazawa; M Goto; T Hata
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Serum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD Patients.

Authors:  Joosep Paats; Annika Adoberg; Jürgen Arund; Annemieke Dhondt; Anders Fernström; Ivo Fridolin; Griet Glorieux; Liisi Leis; Merike Luman; Emilio Gonzalez-Parra; Vanessa Maria Perez-Gomez; Kristjan Pilt; Didier Sanchez-Ospina; Mårten Segelmark; Fredrik Uhlin; Alberto Arduan Ortiz
Journal:  Int J Mol Sci       Date:  2020-02-23       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.